Clinical Trial

Expiratory Muscle Training and Trunk Flexion in Parkinson's Disease

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
Postural abnormalities involving the trunk are prevalent in over 20% of patients with Parkinson's disease (PD). Pathological forward trunk flexion (FTF) is a drug-refractory complication in patients with PD leading to imbalance, pain and fall-related injuries. Deep abdominal muscle training is a key rehabilitation strategy for FTF, as muscles like the transversus abdominis and multifidus are crucial for lumbar stabilization. This training has been shown to improve body position and lumbar proprioception. Abdominal muscles are also responsible for forced expiration. Expiratory muscle strength training (EMST) utilizing forced expiration through expiratory trainer has emerged as a beneficial intervention in the non-pharmacological management of PD, positively impacting clinical aspects such as dysphagia, dystussia, hypokinetic dysarthria, and drooling. EMG study showed large abdominal muscles activity, particularly the transversus abdominis and internus obliquus abdominis during EMST. Therefore, EMST might also be effective in improving lumbar stabilization. Given the established role of abdominal muscles in trunk stabilization, it is plausible that activation of deep abdominal muscles during EMST with the right level of resistance might improve FTF in PD patients. No studies have yet examined the effect of EMST on posture in PD. The primary aim of this study will be to evaluate the effect of EMST on forward trunk flexion in patients with Parkinson's disease. The secondary aim will be to assess the potential duration of the EMST effect on postural abnormalities and its impact on patient stability.
Trial Details
NCT Number NCT06963918
Lead Sponsor General University Hospital, Prague
Conditions Parkinson Disease
Enrollment 30 participants
Start Date 2025-08
Primary Completion 2025-11 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-09